Share This Page
Drug Price Trends for NDC 65862-0286
✉ Email this page to a colleague
Average Pharmacy Cost for 65862-0286
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PERINDOPRIL ERBUMINE 2 MG TAB | 65862-0286-01 | 0.51506 | EACH | 2025-12-17 |
| PERINDOPRIL ERBUMINE 2 MG TAB | 65862-0286-01 | 0.53634 | EACH | 2025-11-19 |
| PERINDOPRIL ERBUMINE 2 MG TAB | 65862-0286-01 | 0.53634 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65862-0286
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 65862-0286
Introduction
The pharmaceutical landscape continuously evolves, driven by innovations in drug development, regulatory shifts, and market dynamics. Among these, detailed market analysis and precise price projections are crucial for stakeholders, including manufacturers, investors, payers, and healthcare providers. This report offers an in-depth analysis of the drug identified under NDC 65862-0286, examining its therapeutic profile, market environment, competitive landscape, and future pricing trends.
Therapeutic Profile and Regulatory Status
The National Drug Code (NDC) 65862-0286 pertains to a specific pharmaceutical product, likely a biologic or small-molecule drug, approved by the U.S. Food and Drug Administration (FDA). Based on available data, this drug appears to target [Insert primary therapeutic area, e.g., oncology, immunology, neurology], addressing conditions such as [Specify conditions]. Its formulation and administration route influence its market positioning, patient access, and reimbursement landscape.
Current regulatory status indicates [approved/under review/pending approval], with patent protection extending until [insert estimated patent expiry]. The expiration timeline influences competitive entry and generic or biosimilar proliferation, critically impacting future price trajectories.
Market Landscape
Market Size and Growth Prospects
The current market for [therapeutic area] drugs is valued at approximately $X billion, with a compound annual growth rate (CAGR) of roughly X% over the next five years, driven by increasing disease prevalence, unmet medical needs, and evolving treatment paradigms. The target patient population for NDC: 65862-0286 is estimated at Y million globally, with North America representing Z% of total sales owing to established healthcare infrastructure and reimbursement policies.
Competitive Environment
NDC: 65862-0286 faces competition from [name key branded and generic competitors]. Notably, biosimilar entrants are anticipated following patent expiry, potentially leading to market share erosion. Established players with robust distribution channels and clinical data advantage could influence pricing strategies.
Recent launches of similar drugs have resulted in price adjustments, often driven by validation of superior efficacy, safety profiles, or value-based pricing strategies. The presence of combination therapies or alternative treatment options further complicates the competitive landscape.
Market Access and Reimbursement Dynamics
Reimbursed pricing is subject to negotiations with [major payers, PBMs, government programs]. Payer strategies increasingly emphasize value-based arrangements, including outcomes-based contracts, which directly influence net pricing and patient out-of-pocket costs.
Pricing Strategies and Projections
Historical Pricing Trends
Initial launch prices for drugs in this category have ranged from $X,000 to $Y,000 per treatment course or dose, reflecting manufacturing costs, R&D investments, and market positioning. Price adjustments post-launch typically occur due to:
- Entry of biosimilars or generics
- Negotiation leverage with payers
- Introduction of new formulations or delivery systems
- Changes in clinical data or approval indications
Current Price Point
As of Q1 2023, the average wholesale price (AWP) for NDC: 65862-0286 is approximately $X,XXX per unit, with net prices after rebates estimated to be $Y,XXX per dose. These figures are aligned with comparable products in the same therapeutic class.
Future Price Trajectory
Projections suggest the price of NDC: 65862-0286 will follow a modest decline or stabilization over the next 3-5 years, influenced by:
- Patent expiry anticipated by [Year], leading to increased biosimilar competition
- Negotiated discounts through value-based agreements
- Market saturation levels and evolving treatment standards
By 2025, the average net price could decrease by X%, reaching approximately $Z,XXX per unit, primarily due to biosimilar entry and increased manufacturer competition.
Impact of Biosimilars and Generics
Biosimilars are expected to capture Y% of the market share within 2-3 years of patent expiry, reducing average selling prices by 30-50%, depending on uptake and payer policies. While biosimilar adoption varies regionally, the U.S. market is expected to see significant generic competition, influencing downward price pressure.
Pricing Optimization Opportunities
Manufacturers could pursue strategies such as:
- Differential pricing for diverse markets
- Value-based contracting to demonstrate clinical benefit
- Formulation innovations to extend patent life or improve adherence
- Educational initiatives to enhance prescriber and patient acceptance
Financial and Business Implications
Given the expected market size and pricing dynamics, early investment into manufacturing capacities, strategic partnerships, and market access initiatives can optimize return on investment. Stakeholders should monitor regulatory developments, patent landscapes, and competitor activity to refine pricing strategies proactively.
Conclusion and Recommendations
The landscape for NDC: 65862-0286 is characterized by gradual price erosion driven by biosimilar competition, evolving reimbursement environments, and patent expiry. Companies should prepare for competitive entry by strengthening value propositions, diversifying formulations, and engaging payers early. Investors need to remain vigilant about regulatory milestones and market share shifts to optimize financial positioning.
Key Takeaways
- Market Size & Growth: The therapeutic area is projected to grow at a CAGR of X%, aligning with rising disease prevalence.
- Price Trends: Current net prices hover around $Y,XXX, with an anticipated decline of X% over five years post-biosimilar entry.
- Competitive Risks: Patent expiry around [Year] will likely accelerate price declines owing to biosimilar proliferation.
- Market Access: Negotiations with payers and inclusion in formularies critically influence realized pricing.
- Strategic Actions: Emphasis on value-based contracting and formulation innovation can preserve margins amid increasing competition.
FAQs
1. When is patent expiry expected for NDC: 65862-0286?
Patent protection is projected to expire in [Year], opening pathways for biosimilar competition and impacting pricing strategies.
2. How will biosimilar entry affect the drug’s price?
Biosimilar entry typically results in a 30-50% reduction in net prices, depending on market adoption and payer policies.
3. Are there approved biosimilars for this drug?
As of the latest data, [list biosimilars if available] are either approved or in development, with regulatory timelines indicating imminent market entry.
4. What factors influence the drug’s pricing in different regions?
Pricing varies due to regional reimbursement policies, market size, negotiation power of payers, and local regulatory frameworks.
5. How can manufacturers extend the product’s market longevity?
Strategies include developing new formulations, securing additional indications, engaging in value-based contracts, and optimizing manufacturing efficiencies.
References
- [Insert source on market size and growth projections]
- [Insert regulator filings or approval data]
- [Insert industry reports on biosimilar market trends]
- [Insert payer and reimbursement policy analyses]
- [Insert patent expiry and legal landscape resources]
Note: Specific data points and timelines should be updated with the latest publicly available information for precise analysis.
More… ↓
